Glasgow Molecular Pathology (GMP) Node
Lead Research Organisation:
University of Glasgow
Department Name: College of Medical, Veterinary, Life Sci
Abstract
The development of treatments for many diseases is slowing, with ever decreasing benefits for patients and dramatic increases in cost. We now understand more about abnormalities in DNA and other molecules which occur in disease. This so-called "molecular pathology" is revealing significant variation in diseases which by standard classifications, for example by a pathologist using a microscope, have been indistinguishable. So, for example, we now know that pancreatic cancer is not just one disease but many different ones, potentially with different treatments.
Armed with this knowledge and the fact that most new treatments are being developed to target specific molecular abnormalities, it is becoming clear that a tailored, stratified approach to patient selection is required for many aspects of disease management. Molecular pathology could revolutionise medical approaches but at the moment only a few tests are routinely available in the NHS and their implementation from research though to clinical practice is complex.
The Glasgow Molecular Pathology Node aims to create a dynamic platform that integrates laboratory medicine, including pathology, and informatics disciplines, which handle and analyse the large datasets which emerge from molecular research. In our Node, scientists, pathologists and colleague clinicians will work together to develop and perform new tests, and interpret, deliver and act on results for patient benefit. Glasgow's existing clinical strengths in pathology and molecular diagnostics are delivered from the purpose-built Laboratory Medicine Building within the new £1billion South Glasgow University Hospital campus, which provides services to 52% of the Scottish population. The University of Glasgow's successful restructure in 2010 created multidisciplinary Research Institutes within the College of Medical, Veterinary and Life Sciences which are perfectly positioned to make use of, and support, the proposal.
Our vision is to transform the management of cancer and chronic disease by accelerating biomedical research, high quality healthcare provision and economic growth. We will achieve this by working in partnership with world-leading discovery researchers from the College's Institutes for Cardiovascular and Medical Sciences, Cancer Sciences and Infection, Immunity and Inflammation, Health Economics, Bio-engineering and Computer Science, and with industry, to create a multidisciplinary centre of excellence in research and development of molecular diagnostic tests.
One of the city of Glasgow's mottos is "people make Glasgow". This was well demonstrated in the recent 2014 Commonwealth Games which were full of "people, place and passion" and our vision is to develop the people, infrastructure and collaborative working practices to enable validation and delivery of high-quality molecular pathology.
Our strategic focus and objectives are therefore to build capacity in molecular pathology and informatics, through funding for flexible and additional staffing and dedicated high-quality training to develop expertise. This will enable enhanced delivery and development of clinical molecular pathology; and will underpin the parallel development of pipelines for molecular diagnostics validation.
*We will develop new tests to better diagnose patients and guide their best treatment in cancer, in inflammatory diseases like rheumatoid arthritis, and in cardiovascular and metabolic disease like diabetes, heart disease and stroke.
Successful realisation of this vision will:
*Maximise the impact of major recent infrastructure investment;
*Create the next generation of leaders;
*Deliver high impact innovation in molecular pathology and complex informatics, with underpinning health economic input, to the
*Benefit of the health and economy of the UK, encompassing NHS care, academic research and UK industry; and
*Contribute a critical Node to this successful new UK network.
Armed with this knowledge and the fact that most new treatments are being developed to target specific molecular abnormalities, it is becoming clear that a tailored, stratified approach to patient selection is required for many aspects of disease management. Molecular pathology could revolutionise medical approaches but at the moment only a few tests are routinely available in the NHS and their implementation from research though to clinical practice is complex.
The Glasgow Molecular Pathology Node aims to create a dynamic platform that integrates laboratory medicine, including pathology, and informatics disciplines, which handle and analyse the large datasets which emerge from molecular research. In our Node, scientists, pathologists and colleague clinicians will work together to develop and perform new tests, and interpret, deliver and act on results for patient benefit. Glasgow's existing clinical strengths in pathology and molecular diagnostics are delivered from the purpose-built Laboratory Medicine Building within the new £1billion South Glasgow University Hospital campus, which provides services to 52% of the Scottish population. The University of Glasgow's successful restructure in 2010 created multidisciplinary Research Institutes within the College of Medical, Veterinary and Life Sciences which are perfectly positioned to make use of, and support, the proposal.
Our vision is to transform the management of cancer and chronic disease by accelerating biomedical research, high quality healthcare provision and economic growth. We will achieve this by working in partnership with world-leading discovery researchers from the College's Institutes for Cardiovascular and Medical Sciences, Cancer Sciences and Infection, Immunity and Inflammation, Health Economics, Bio-engineering and Computer Science, and with industry, to create a multidisciplinary centre of excellence in research and development of molecular diagnostic tests.
One of the city of Glasgow's mottos is "people make Glasgow". This was well demonstrated in the recent 2014 Commonwealth Games which were full of "people, place and passion" and our vision is to develop the people, infrastructure and collaborative working practices to enable validation and delivery of high-quality molecular pathology.
Our strategic focus and objectives are therefore to build capacity in molecular pathology and informatics, through funding for flexible and additional staffing and dedicated high-quality training to develop expertise. This will enable enhanced delivery and development of clinical molecular pathology; and will underpin the parallel development of pipelines for molecular diagnostics validation.
*We will develop new tests to better diagnose patients and guide their best treatment in cancer, in inflammatory diseases like rheumatoid arthritis, and in cardiovascular and metabolic disease like diabetes, heart disease and stroke.
Successful realisation of this vision will:
*Maximise the impact of major recent infrastructure investment;
*Create the next generation of leaders;
*Deliver high impact innovation in molecular pathology and complex informatics, with underpinning health economic input, to the
*Benefit of the health and economy of the UK, encompassing NHS care, academic research and UK industry; and
*Contribute a critical Node to this successful new UK network.
Technical Summary
Glasgow is ideally positioned to become a Molecular Pathology Node. Our existing clinical strengths in pathology and molecular diagnostics are delivered from the purpose-built Laboratory Medicine Building within our new £1billion South Glasgow University Hospital campus (SGUH), which provides services to 52% of the Scottish population. The University of Glasgow's successful restructure in 2010 created multidisciplinary Research Institutes within the College of Medical, Veterinary and Life Sciences (MVLS) which are perfectly positioned to make use of, and support, the GMP Node proposal.
Our vision is to transform the management of cancer and chronic disease by accelerating biomedical research, high quality healthcare provision and economic growth. We will achieve this by working in partnership with discovery researchers from the College's Institutes for Cancer Sciences, Infection, Immunity and Inflammation, and Cardiovascular and Medical Sciences, and with industry, to create a multidisciplinary centre of excellence in research and development of molecular diagnostic tests.
Our strategic focus and objectives are to enhance our capabilities in molecular pathology and informatics, through funding for staffing and high-quality training to further build capacity and expertise. This will enable greater delivery and development of clinical molecular pathology; and will underpin the parallel development of pipelines for molecular diagnostics from discovery through validation and implementation.
Successful realisation of this vision will:
* Maximise the impact of major recent infrastructure investment;
* Create the next generation of leaders;
* Deliver high impact innovation in molecular pathology and complex informatics for the benefit of NHS care, academic research and UK industry; and
* Contribute a critical Node to this successful new UK network.
Our vision is to transform the management of cancer and chronic disease by accelerating biomedical research, high quality healthcare provision and economic growth. We will achieve this by working in partnership with discovery researchers from the College's Institutes for Cancer Sciences, Infection, Immunity and Inflammation, and Cardiovascular and Medical Sciences, and with industry, to create a multidisciplinary centre of excellence in research and development of molecular diagnostic tests.
Our strategic focus and objectives are to enhance our capabilities in molecular pathology and informatics, through funding for staffing and high-quality training to further build capacity and expertise. This will enable greater delivery and development of clinical molecular pathology; and will underpin the parallel development of pipelines for molecular diagnostics from discovery through validation and implementation.
Successful realisation of this vision will:
* Maximise the impact of major recent infrastructure investment;
* Create the next generation of leaders;
* Deliver high impact innovation in molecular pathology and complex informatics for the benefit of NHS care, academic research and UK industry; and
* Contribute a critical Node to this successful new UK network.
Planned Impact
Who will benefit from the programme?
While there has been significant advancement in identifying molecular biomarkers and molecular mechanisms of disease, translation to the clinic has been lagging. Through the node this should be expedited so that benefits in the early prediction, prevention and improved management (including personalized approaches) can be realised.
Those who would benefit include:
Patients - we will identify and establish new biomarkers with diagnostic potential in cancer, inflammation and cardiovascular diseases. These outputs will a) hold potential in patient treatment stratification strategies; b) facilitate earlier disease diagnosis; and c) ensure more accurate analysis of diseased tissues. The diagnostics developed will be integrated in healthcare practice helping to improve patient treatment strategies and the manage disease through earlier and more accurate diagnosis.
Researchers and academic community- through development of new molecular assays to assist in mechanistic insights of human disease. We will be able to provide unique resources, tools and databases linked to deeply phenotyped patients with relevant diseases.
Clinicians - through improved prediction, diagnosis and management of patients with relevant disease. Novel validated biomarkers could be incorporated into clinical guidelines and as such impact on clinical care.
NHS and clinical service laboratories - Novel micro-assays of health and disease that will be developed through the Node can be transferred to clinical service laboratories for rapid non-invasive diagnostics that could be used in the clinic.
Industry - will have the opportunity to directly develop, test and validate their platform technologies in an optimal integrated healthcare environment advancing application into practice. Partners will collaborate on multidisciplinary research which will feed on-going developments and enhance their product portfolios. Association with the Node offers SME and Corporate partners the opportunity to further strengthen their reputation internationally, driving longer term economic impact.
Industry participation in training will help to build capacity creating a workforce in hospital practice and primary care capable of developing, interpreting and applying the results of novel molecular tests. This will support the adoption of standardised procedures and processes, optimising practice nationally and beyond. Downstream it is anticipated that this will influence policy-makers in government agencies and regulators to drive new policy changes in treatment and diagnosis.
Pharmaceutical and biotech companies - By identifying novel molecular drug targets as a result of deciphering mechanisms of disease at the molecular level (through validated biomarkers), new therapeutic approaches and drugs will be developed. For example, microparticles as a therapeutic delivery system; microRNA and LnRNA as targets; new or repurposed drug development etc.
Pharma, food industry and regulatory bodies - benefit from the ability to demonstrate potentially positive effects from intervention based on the impact on proteomic biomarkers, which can be employed as surrogates for hard endpoints. Similarly, regulatory agencies can benefit from these surrogates, enabling assessment of benefits, but also potentially harmful effects of novel drugs.
Data management and analysis - Underpinning development is the management of vast datasets. The Node provides the opportunity to develop new informatics and data management systems which integrate across a wide range of diseases and sample types eg tissues and imaging. The close interaction with NHS Greater Glasgow and Clyde Health Board will help to define user functionality and product specification requirements for early adoption within the NHS.
While there has been significant advancement in identifying molecular biomarkers and molecular mechanisms of disease, translation to the clinic has been lagging. Through the node this should be expedited so that benefits in the early prediction, prevention and improved management (including personalized approaches) can be realised.
Those who would benefit include:
Patients - we will identify and establish new biomarkers with diagnostic potential in cancer, inflammation and cardiovascular diseases. These outputs will a) hold potential in patient treatment stratification strategies; b) facilitate earlier disease diagnosis; and c) ensure more accurate analysis of diseased tissues. The diagnostics developed will be integrated in healthcare practice helping to improve patient treatment strategies and the manage disease through earlier and more accurate diagnosis.
Researchers and academic community- through development of new molecular assays to assist in mechanistic insights of human disease. We will be able to provide unique resources, tools and databases linked to deeply phenotyped patients with relevant diseases.
Clinicians - through improved prediction, diagnosis and management of patients with relevant disease. Novel validated biomarkers could be incorporated into clinical guidelines and as such impact on clinical care.
NHS and clinical service laboratories - Novel micro-assays of health and disease that will be developed through the Node can be transferred to clinical service laboratories for rapid non-invasive diagnostics that could be used in the clinic.
Industry - will have the opportunity to directly develop, test and validate their platform technologies in an optimal integrated healthcare environment advancing application into practice. Partners will collaborate on multidisciplinary research which will feed on-going developments and enhance their product portfolios. Association with the Node offers SME and Corporate partners the opportunity to further strengthen their reputation internationally, driving longer term economic impact.
Industry participation in training will help to build capacity creating a workforce in hospital practice and primary care capable of developing, interpreting and applying the results of novel molecular tests. This will support the adoption of standardised procedures and processes, optimising practice nationally and beyond. Downstream it is anticipated that this will influence policy-makers in government agencies and regulators to drive new policy changes in treatment and diagnosis.
Pharmaceutical and biotech companies - By identifying novel molecular drug targets as a result of deciphering mechanisms of disease at the molecular level (through validated biomarkers), new therapeutic approaches and drugs will be developed. For example, microparticles as a therapeutic delivery system; microRNA and LnRNA as targets; new or repurposed drug development etc.
Pharma, food industry and regulatory bodies - benefit from the ability to demonstrate potentially positive effects from intervention based on the impact on proteomic biomarkers, which can be employed as surrogates for hard endpoints. Similarly, regulatory agencies can benefit from these surrogates, enabling assessment of benefits, but also potentially harmful effects of novel drugs.
Data management and analysis - Underpinning development is the management of vast datasets. The Node provides the opportunity to develop new informatics and data management systems which integrate across a wide range of diseases and sample types eg tissues and imaging. The close interaction with NHS Greater Glasgow and Clyde Health Board will help to define user functionality and product specification requirements for early adoption within the NHS.
Organisations
- University of Glasgow (Lead Research Organisation)
- Engineering and Physical Sciences Research Council (Co-funder)
- University of Manchester (Collaboration)
- LEICA BIOSYSTEMS (Collaboration)
- East Midlands Breathomics Pathology Node (Collaboration)
- NHS Greater Glasgow and Clyde (NHSGGC) (Collaboration)
- Glasgow Royal Infirmary (Collaboration)
- Thermo Fisher Scientific (United Kingdom) (Collaboration)
- National Cancer Research Institute (NCRI) (Collaboration)
- Nottingham Molecular Pathology Node (Collaboration)
- Sistemic Ltd (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- STRATIFIED MEDICINE SCOTLAND INNOVATION CENTRE (Collaboration)
- Edinburgh-St Andrews Consortium for Molecular Pathology Node (Collaboration)
- Newcastle Molecular Pathology Node (Collaboration)
- Illumina Inc. (Collaboration)
- BioClavis Ltd (Collaboration)
- ARIDHIA INFORMATICS LIMITED (Collaboration)
- Aridhia (United Kingdom) (Project Partner)
- Leica Biosystems (Project Partner)
- Sistemic Scotland Ltd (Project Partner)
Publications
Salvi E
(2017)
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.
in Hypertension (Dallas, Tex. : 1979)
Sattar N
(2016)
Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure.
in The lancet. Diabetes & endocrinology
Savoia C
(2017)
Personalized medicine-a modern approach for the diagnosis and management of hypertension.
in Clinical science (London, England : 1979)
Scarpa A
(2017)
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours.
in Nature
Scarpa A
(2017)
Whole-genome landscape of pancreatic neuroendocrine tumours.
in Nature
Scott P
(2017)
Addendum to Informatics for Health 2017: Advancing both science and practice.
in Journal of innovation in health informatics
Scott PJ
(2017)
Informatics for Health 2017: Advancing both science and practice.
in Journal of innovation in health informatics
Siebert S
(2017)
Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups.
in Scientific reports
Sliz E
(2018)
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
in Circulation
Swanton C
(2016)
Consensus on precision medicine for metastatic cancers: a report from the MAP conference.
in Annals of oncology : official journal of the European Society for Medical Oncology
| Description | Additional capacity and expertise |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | NHSGGC genetics is a nationally recognised and funded training centre for pre-registration clinical scientists. The Node has funded 2 trainees to undertake a model scientist trainig programme for molecular pathology. These posts epitomise development of capacity and expertise. Additionally, for existing consultant pathologists, buy-out of individual four-hour sessions provides dedicated time, aiming to increase expertise in molecular pathology through training; and to train others in pathology, especially scientific staff in Genetics. Together this staffing is enhancing and expanding multi-disciplinary working for development and delivery of molecular pathology. |
| Description | Bioinformatics scholarship for clinical scientist |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Board Member of James IV Association of Surgeons |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| URL | http://www.jamesivassociationsurgeons.com/ |
| Description | Brain Tumour Round Table Summit |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Description | Development of a new educational website (providing access to many high quality international databases and educational resources). This website, www.EuroGEMS.org was created by Prof Tobias and presented in detail to the Education Committee and then the Executive Board of the European Society of Human Genetics (at their international annual conference, in Milan, in June 2018). Subsequently, it was fully endorsed and named on the official ESHG website as the main source for online Educational Materials, for professionals, educators, researchers, patients and relatives. |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | The educational website (providing access to many high quality international databases and educational resources), www.EuroGEMS.org was created, presented in detail to the Education Committee and then the Executive Board of the European Society of Human Genetics (at their international annual conference, in Milan, in June 2018). After being fully endorsed by the ESHG and signposted on the official ESHG website as the main source for online Educational Materials, the website was established online. There were approximately 3000 visitors in just the first 6 months, from approximately 80 countries. |
| URL | https://www.eshg.org/education.0.html |
| Description | Invited member of Steering Committee of the Roadmap for the Early Detection and Diagnosis of Cancer, May 2019 - current. CRUK and other cancer stakeholders. |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Membership of a guideline committee |
| Description | Invited member of the NHS England Innovation Expert Advisory Group for the National Cancer Programme, Dec 2019 - current. |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Masters in Molecular Pathology |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Seventeen students, from the West of Scotland, are currently enrolled in the Masters in Molecular Pathology; 12 trainee pathologists and 5 clinical/biomedical scientists.The multi-disciplinary training, which includes pathology, genetics and exposure to other laboratory medicine specialities, provided as part of the Masters in Molecular Pathology is developing a workforce with appropriate expertise to develop, undertake, interpret and apply the results of novel diagnostics. This is leading to enhanced capacity and expertise which will result in improvements in clinical service delivery. |
| Description | Scottish Funding Council review of Research Pooling |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://www.universities-scotland.ac.uk/briefing-evidence/independent-review-scottish-funding-counci... |
| Description | Scottish Precision Medicine and Innovation Audit, commissioned by BEIS. |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://www.gla.ac.uk/media/Media_639170_smxx.pdf |
| Description | Upskilling of clinical scientist to apply bioinformatics tools in the clinical setting |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | This training has allowed bioinformatics practices (bioinformatics is the science of creating and using software packages to interpret the extremely large-scale data arising from any genetic studies, whether genomic, transcriptomic, proteomic, or metabolomic) to be applied in diagnostic human genomics for germline (inherited) and somatic (cancer) genetic disease.Next generation sequencing is a technology which has transformed the delivery of genetics services to the NHS. We are able to look at many more genes than ever before, and can give more patients a diagnosis, prognosis or therapeutic outcome by using this technology. However complex data analysis from these tests can be challenging and therefore the development of bioinformatics expertise within the NHS is key to the future delivery of our services. With this knowledge and skills attained the clinical scientist is now able to maintain an existing analytical pipeline, and be part of their development. This could potentially improve their cost-effectiveness and turn-around-time with more efficient software, or create new pipelines required by further service requirements. |
| Description | Beatson Endowment |
| Amount | £500,000 (GBP) |
| Organisation | Beatson Cancer Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2022 |
| Description | Beatson Endowment |
| Amount | £300,000 (GBP) |
| Organisation | Beatson Cancer Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2018 |
| Description | Cancer Research UK |
| Amount | £10,000,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 01/2023 |
| Description | Confidence in Concept |
| Amount | £400,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2020 |
| Description | Confidence in concept |
| Amount | £280,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 04/2017 |
| Description | Glasgow Precision Diagnostics and Therapeutics |
| Amount | £413,000 (GBP) |
| Funding ID | MC_PC_17160 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2020 |
| Description | Glasgow University MVLS EPSRC Centre for Doctoral Training Student - CDT funded studentship |
| Amount | £80,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | I-CAIRD: Industrial Centre for AI Research in Digital Diagnostics |
| Amount | £11,608,211 (GBP) |
| Funding ID | 104690 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 01/2023 |
| Description | Integrated Technologies for Improved Polyp Surveillance (INCISE) |
| Amount | £2,349,971 (GBP) |
| Funding ID | 105858 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 04/2023 |
| Description | KTP (Knowledge Transfer Partnership) |
| Amount | £260,000 (GBP) |
| Funding ID | 12310 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 07/2023 |
| Description | Precision-Panc: a dynamic therapeutic development platform for pancreatic cancer |
| Amount | £2,632,051 (GBP) |
| Funding ID | 23526 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2022 |
| Description | Proximity to discovery: Industry engagement fund |
| Amount | £110,000 (GBP) |
| Funding ID | MC_PC_16073 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 04/2017 |
| Description | SteatoSITE - An integrated gene-to-patient data commons for NAFLD research |
| Amount | £1,668,587 (GBP) |
| Funding ID | 104209 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2018 |
| End | 03/2021 |
| Title | Diagnostic biomarkers for African trypanosomiasis staging |
| Description | Metabolite profile that diagnoses patients with African trypanosomiasis and also stage 1 vs stage 2 disease |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | Metabolomics characterisation of new biomarkers for human African trypanosomiasis diagnosis and staging |
| URL | http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005140 |
| Title | Quantification of Carboxymethyl lysine in plasma using isotope dilution mass spectromtry |
| Description | Naomi developed a high throughput 96-well based sample preparation method for reduction and hydrolysis of plasma samples prior to carboxymethyl lysine (CML) analysis. Naomi also investigated alternative liquid chromatography methods for isolation of CML and optimised the detection of CML on an Orbitrap Exactive mass spectrometer. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2017 |
| Provided To Others? | No |
| Impact | Previous methods of sample preparation have been very time consuming and limited application of isotope dilution mass spectrometry methods in large cohorts. As a result of this conflicting results have been found for association of CML with disease. ELISA methods have been used to measure CML, unfortunately these assays suffer from interference and steric hinderance and so again conflicting results have been obtained. Development of a high throughput assay has allowed CML to be measured in the British Regional Heart study (1700 samples). Collaborators are currently using the results provided to look for associations between CML and disease. Naomi is currently preparing a manuscript for submission so that other researchers can use this method. |
| Title | Glasgow Molecular Pathology Node Tissue Annotation Dataset |
| Description | A system of web screens designed for one particular study has been extended by a Node application developer to encompass *any* project involving blood or tissue samples providing a core 'tissue annotation' dataset across multiple projects. Basic donor identifiers are recorded along with date of consent, then details of each sample are recorded according to the processes involved with that particular sample. Sample data include the nature of the sample, performance status of donor, primary diagnosis, pathology information, timings of any processing done from surgery through to end of fixation, date of sections, DNA concentration/volume, and mutation statuses. Each sample can then be assigned to one or more projects, each of which may have its own specific set of data requirements. For example Precision Panc has an extended pathology dataset. These project-specific requirements are added to the database application as required. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | Firstly, recording sample data in this database links directly to the Greater Glasgow and Clyde Safe Haven, which enables routinely collected clinical data to be associated with each of the sample records stored in the system. For research purposes, so long as the required permissions are in place, this provides the potential of linking full clinical history and any follow-up information relevant to the original sample records without exposing anything that could be used to identify an individual. Secondly, this standard dataset across multiple projects will be a valuable source of audit data. In sample processing, for example, we will be able to retrospectively examine how the various processes involved in producing a research sample can affect the viability of the sample for next generation sequencing. Finally, the database system automates production of anonymised XML files for transferring sample information to other centres and processes any associated new data returned. Removing the need to manually transcribe information from the database to spreadsheets, etc., removes any chance of human error and frees up staff from having to spend time on these tasks. |
| Description | Collaboration between NHSGGC pathology and ICAMS |
| Organisation | Glasgow Royal Infirmary |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Two cardiovascular pathologists are developing a 'fibrosis platform' that will allow for best practice assessment of fibrosis. This platform will include new histological approaches as well as assessment of molecular markers of fibrosis and inflammation. |
| Collaborator Contribution | The Institute of Cardiovascular and Metabolic diseases (ICAMS) is providing slides from a model of cardiac and vascular hypertropy to facilitate model development. |
| Impact | This collaboration offers a developmental and training opportunity for pathologists and allows NHS pathologists to participate in ICAMS research and to participate in the preparation of grant applications and papers. |
| Start Year | 2016 |
| Description | Collaboration with Aridhia Informatics |
| Organisation | Aridhia Informatics Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Node is providing Aridhia with the opportunity to test feasibility of their informatics platform and to progress the development of these into clinical practice. This allows Aridhia to optimise their platforms for application into a healthcare setting and to fast-track the adoption of platform improvements or new products/services into practice. |
| Collaborator Contribution | Aridhia are contributing a development licence (including upgrades) in respect of its proprietary AnalytiXagility Data safe haven service. This contribution has added to the infrastructure available through the Node and supports the research workstrands. |
| Impact | No outputs or outcomes have resulted from this partnership yet. |
| Start Year | 2015 |
| Description | Collaboration with BioClavis |
| Organisation | BioClavis Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Node provides a common infrastructure of staff, expertise and research development activities to support molecular diagnostic delivery and development. The Node offers collaborators the opportunity to test the feasbility of diagnostic developments and progress the devlopment of these and their application into clinical practice in fundamental areas of unmet need: cancer, inflammation and cardiovascular diseases. This collaboration will offer BioClavis the opportunity to validate and test the feasbility of targeted panels using the TempO-Seq platform in an end-user environment.This will allow BioClavis to expedite the application and adoption of targeted molecular panels into laboratory healthcare practice. |
| Collaborator Contribution | BioClavis and the TempO-Seq platform offers the Node the ability to efficiently analyze large cohorts with customizable biomarker panels from the whole transcriptome for discovery work down to biomarker panels of tens to hundreds of genes, quickly and inexpensively. The versatility of the technology allows the same assay chemistry to be run on purified RNA during discovery phase, or whole blood (and other tissues) for efficient use in clinical implementation. The highly precise assay results (low CVs) has been demonstrated to more effectively identify small changes in differential expression, potentially enabling a more sensitive or accurate test. The collaboration will allow the Node to access the unique TempO-Seq platform which will help to accelerate our world-class discovery research supporting new molecular diagnostic developments and precision medicine strategies. Together, this strong partnership will deliver world-leading diagnostic tests for diagnostic areas of NHS and patient need, at a disruptive price compared to existing technologies. |
| Impact | None yet |
| Start Year | 2017 |
| Description | Collaboration with Illumina |
| Organisation | Illumina Inc. |
| Department | Illumina Cambridge Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Together, Glasgow and Illumina plan to evaluate and consider eventual implementation of an NGS-based panel for evaluation of actionable mutations. The samples will be reviewed by a pathologist before sequencing. NHSGGC will provide laboratory space and instrumentation, basic laboratory consumables and staff to run the assay locally. |
| Collaborator Contribution | Illumina provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. |
| Impact | No outputs or outcomes have resulted from this partnership yet. |
| Start Year | 2016 |
| Description | Collaboration with Leica Biosystems |
| Organisation | Leica Biosystems |
| Country | Germany |
| Sector | Private |
| PI Contribution | The Node is providing Leica the opportunity to test the feasiblity of tissue sample processing procedures and protocols and validate these in an end-user setting. This will help to expedite their application and adoption into laboratory healthcare practice. |
| Collaborator Contribution | In addition to providing instrumentation and tissue processing consumables, labour, reagents and contribution for tests, Leica are providing know-how and expertise, project management support and development costs. |
| Impact | No outputs or outcomes have resulted from this partnership yet. |
| Start Year | 2015 |
| Description | Collaboration with NHSGGC Joint Working Project |
| Organisation | NHS Greater Glasgow and Clyde (NHSGGC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | The Node is providing health economic expertise and is developing a health economic model to evaluate health economic and QALYS benefits associated with the introduction of a myeloid neoplasm panel into clinical practice in Scotland. |
| Collaborator Contribution | The Joint Working Project is providing the expertise of an NGS scientist and consumables to undertake a evaluation and validation of the myeloid neoplasm panel for clinical practice. |
| Impact | No outputs or outcomes have resulted from this partnership yet. |
| Start Year | 2016 |
| Description | Collaboration with Sistemic Scotland |
| Organisation | Sistemic Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Node offers Sistemic the opportunity to test the feasibility of diagnostic developments and progress the development of these and their application into clinical practice in fundamental areas of unmet need: cancer, inflammation and cardiovascular diseases. This will enable Sistemic to further validate the diagnostic potential of their miRNA platform. The Node provides access to unprecedented infrastructure, a test-bed offering Sistemic the opportunity to optimise their platform for potential application into a healthcare setting. |
| Collaborator Contribution | Sistemic have offered their proprietary SistemRNS miRNA profiling technology, databases, algorithms, SOPs and staff expertise. |
| Impact | No outputs or outcomes have resulted from this partnership yet. |
| Start Year | 2015 |
| Description | Collaboration with ThermoFisher |
| Organisation | Thermo Fisher Scientific |
| Country | United States |
| Sector | Private |
| PI Contribution | We provide links with academics, clinicians, clinical and biomedical scientists to help ThermoFisher in the development of their product portfolios and offer new technologies to help support impact and economic growth. |
| Collaborator Contribution | ThermoFisher have provided access to a comprehensive range of ThermoFisher Scientific products, and, in particular, provision of preferential discounts on products. Additonally training, education, seminars and workshops are provided by ThermoFisher as needed where practicable. |
| Impact | No outputs or outcomes have resulted from this partnership yet. |
| Start Year | 2016 |
| Description | Cross Node Training workstrand collaboration |
| Organisation | East Midlands Breathomics Pathology Node |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Glasgow Molecular Pathology Node is leading a series of teleconference calls across the Node network to explore opportunities for alignment, complementarity and shared learning within the Node network and with external stakeholders. The focus of these discussions is to support and lead training developments in Molecular Pathology. |
| Collaborator Contribution | The training leads and associated staff are participating in these calls and sharing knowledge, training activities, planned Masters level curricula and ideas for sharing and potential harmonisation of curricula in Molecular Pathology. |
| Impact | These calls have resulted in a partnership between the Node network and CM-Path. Professor Louise Jones, Training workstream lead for CM-Path is a regular participant in these calls and the Molecular Pathology Nodes and CM-Path are working together to explore support for and implementation of changes to pathology training with the Royal College of Pathologists |
| Start Year | 2015 |
| Description | Cross Node Training workstrand collaboration |
| Organisation | Edinburgh-St Andrews Consortium for Molecular Pathology Node |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Glasgow Molecular Pathology Node is leading a series of teleconference calls across the Node network to explore opportunities for alignment, complementarity and shared learning within the Node network and with external stakeholders. The focus of these discussions is to support and lead training developments in Molecular Pathology. |
| Collaborator Contribution | The training leads and associated staff are participating in these calls and sharing knowledge, training activities, planned Masters level curricula and ideas for sharing and potential harmonisation of curricula in Molecular Pathology. |
| Impact | These calls have resulted in a partnership between the Node network and CM-Path. Professor Louise Jones, Training workstream lead for CM-Path is a regular participant in these calls and the Molecular Pathology Nodes and CM-Path are working together to explore support for and implementation of changes to pathology training with the Royal College of Pathologists |
| Start Year | 2015 |
| Description | Cross Node Training workstrand collaboration |
| Organisation | Newcastle Molecular Pathology Node |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Glasgow Molecular Pathology Node is leading a series of teleconference calls across the Node network to explore opportunities for alignment, complementarity and shared learning within the Node network and with external stakeholders. The focus of these discussions is to support and lead training developments in Molecular Pathology. |
| Collaborator Contribution | The training leads and associated staff are participating in these calls and sharing knowledge, training activities, planned Masters level curricula and ideas for sharing and potential harmonisation of curricula in Molecular Pathology. |
| Impact | These calls have resulted in a partnership between the Node network and CM-Path. Professor Louise Jones, Training workstream lead for CM-Path is a regular participant in these calls and the Molecular Pathology Nodes and CM-Path are working together to explore support for and implementation of changes to pathology training with the Royal College of Pathologists |
| Start Year | 2015 |
| Description | Cross Node Training workstrand collaboration |
| Organisation | Nottingham Molecular Pathology Node |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | The Glasgow Molecular Pathology Node is leading a series of teleconference calls across the Node network to explore opportunities for alignment, complementarity and shared learning within the Node network and with external stakeholders. The focus of these discussions is to support and lead training developments in Molecular Pathology. |
| Collaborator Contribution | The training leads and associated staff are participating in these calls and sharing knowledge, training activities, planned Masters level curricula and ideas for sharing and potential harmonisation of curricula in Molecular Pathology. |
| Impact | These calls have resulted in a partnership between the Node network and CM-Path. Professor Louise Jones, Training workstream lead for CM-Path is a regular participant in these calls and the Molecular Pathology Nodes and CM-Path are working together to explore support for and implementation of changes to pathology training with the Royal College of Pathologists |
| Start Year | 2015 |
| Description | Cross Node Training workstrand collaboration |
| Organisation | University of Manchester |
| Department | Manchester Molecular Pathology Innovation Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The Glasgow Molecular Pathology Node is leading a series of teleconference calls across the Node network to explore opportunities for alignment, complementarity and shared learning within the Node network and with external stakeholders. The focus of these discussions is to support and lead training developments in Molecular Pathology. |
| Collaborator Contribution | The training leads and associated staff are participating in these calls and sharing knowledge, training activities, planned Masters level curricula and ideas for sharing and potential harmonisation of curricula in Molecular Pathology. |
| Impact | These calls have resulted in a partnership between the Node network and CM-Path. Professor Louise Jones, Training workstream lead for CM-Path is a regular participant in these calls and the Molecular Pathology Nodes and CM-Path are working together to explore support for and implementation of changes to pathology training with the Royal College of Pathologists |
| Start Year | 2015 |
| Description | Cross Node health economics partnership |
| Organisation | East Midlands Breathomics Pathology Node |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Glasgow Molecular Pathology Node is leading on Node network discussions which have identified a number of areas of complementary work and common challenges/issues for health economic assessment of diagnostics and devices. Four themes were originally identified and a series of teleconferences and workshops were held that involved the preparation of working papers by each Node. Glasgow has led on 'Early methods of health technology assessment' - with a literature review and discussion papers prepared. |
| Collaborator Contribution | The East Midlands Breathomics Molecular Pathology Node are leading on 'Trial design'; Manchester Molecular Pathology Innovation Centre are leading on 'Reimbursement policy and informational requirements; and Newcastle Molecular Pathology Node are leading on 'Whole disease modelling'. A number of working papers are being prepared to facilitate further discussion and to identify further opportunities for cross Node working. |
| Impact | Two cross Node workshops which have also included representatives from the DECs were held in 2017. A joint poster was presented at the International Society For Pharmacoeconomics and Outcomes Research conference in November 2017. |
| Start Year | 2016 |
| Description | Cross Node health economics partnership |
| Organisation | Edinburgh-St Andrews Consortium for Molecular Pathology Node |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Glasgow Molecular Pathology Node is leading on Node network discussions which have identified a number of areas of complementary work and common challenges/issues for health economic assessment of diagnostics and devices. Four themes were originally identified and a series of teleconferences and workshops were held that involved the preparation of working papers by each Node. Glasgow has led on 'Early methods of health technology assessment' - with a literature review and discussion papers prepared. |
| Collaborator Contribution | The East Midlands Breathomics Molecular Pathology Node are leading on 'Trial design'; Manchester Molecular Pathology Innovation Centre are leading on 'Reimbursement policy and informational requirements; and Newcastle Molecular Pathology Node are leading on 'Whole disease modelling'. A number of working papers are being prepared to facilitate further discussion and to identify further opportunities for cross Node working. |
| Impact | Two cross Node workshops which have also included representatives from the DECs were held in 2017. A joint poster was presented at the International Society For Pharmacoeconomics and Outcomes Research conference in November 2017. |
| Start Year | 2016 |
| Description | Cross Node health economics partnership |
| Organisation | Newcastle Molecular Pathology Node |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Glasgow Molecular Pathology Node is leading on Node network discussions which have identified a number of areas of complementary work and common challenges/issues for health economic assessment of diagnostics and devices. Four themes were originally identified and a series of teleconferences and workshops were held that involved the preparation of working papers by each Node. Glasgow has led on 'Early methods of health technology assessment' - with a literature review and discussion papers prepared. |
| Collaborator Contribution | The East Midlands Breathomics Molecular Pathology Node are leading on 'Trial design'; Manchester Molecular Pathology Innovation Centre are leading on 'Reimbursement policy and informational requirements; and Newcastle Molecular Pathology Node are leading on 'Whole disease modelling'. A number of working papers are being prepared to facilitate further discussion and to identify further opportunities for cross Node working. |
| Impact | Two cross Node workshops which have also included representatives from the DECs were held in 2017. A joint poster was presented at the International Society For Pharmacoeconomics and Outcomes Research conference in November 2017. |
| Start Year | 2016 |
| Description | Cross Node health economics partnership |
| Organisation | Nottingham Molecular Pathology Node |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | The Glasgow Molecular Pathology Node is leading on Node network discussions which have identified a number of areas of complementary work and common challenges/issues for health economic assessment of diagnostics and devices. Four themes were originally identified and a series of teleconferences and workshops were held that involved the preparation of working papers by each Node. Glasgow has led on 'Early methods of health technology assessment' - with a literature review and discussion papers prepared. |
| Collaborator Contribution | The East Midlands Breathomics Molecular Pathology Node are leading on 'Trial design'; Manchester Molecular Pathology Innovation Centre are leading on 'Reimbursement policy and informational requirements; and Newcastle Molecular Pathology Node are leading on 'Whole disease modelling'. A number of working papers are being prepared to facilitate further discussion and to identify further opportunities for cross Node working. |
| Impact | Two cross Node workshops which have also included representatives from the DECs were held in 2017. A joint poster was presented at the International Society For Pharmacoeconomics and Outcomes Research conference in November 2017. |
| Start Year | 2016 |
| Description | Cross Node health economics partnership |
| Organisation | University of Manchester |
| Department | Manchester Molecular Pathology Innovation Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The Glasgow Molecular Pathology Node is leading on Node network discussions which have identified a number of areas of complementary work and common challenges/issues for health economic assessment of diagnostics and devices. Four themes were originally identified and a series of teleconferences and workshops were held that involved the preparation of working papers by each Node. Glasgow has led on 'Early methods of health technology assessment' - with a literature review and discussion papers prepared. |
| Collaborator Contribution | The East Midlands Breathomics Molecular Pathology Node are leading on 'Trial design'; Manchester Molecular Pathology Innovation Centre are leading on 'Reimbursement policy and informational requirements; and Newcastle Molecular Pathology Node are leading on 'Whole disease modelling'. A number of working papers are being prepared to facilitate further discussion and to identify further opportunities for cross Node working. |
| Impact | Two cross Node workshops which have also included representatives from the DECs were held in 2017. A joint poster was presented at the International Society For Pharmacoeconomics and Outcomes Research conference in November 2017. |
| Start Year | 2016 |
| Description | Cross Node informatics workshops |
| Organisation | East Midlands Breathomics Pathology Node |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Glasgow Molecular Pathology Node has led a series of calls and workshops across the Node network to provide the opportunity for each of the Nodes to learn about the bioinformatics work being undertaken and to facilitate discussion and to prioritise areas for further collaboration/cross Node training opportunities. In addition to an increased awareness of the specific work being undertaken a number of common themes were identified: data integration of multiomics; clinical data collection and integration; image analysis and training. The focus of ongoing workshops and discussions is to consider how the Node network can work together to address common challenges and support Node activities. |
| Collaborator Contribution | The informaticians associated with each Node have participated in calls, online seminars and workshops to share information, experiences and to offer solutions. Additionally the team in Manchester are organsing a cross Node informatics research symposium which provides informaticians with the opportunity to showcase the informatics work being undertaken across the Nodes. |
| Impact | No outcomes or impact have resulted from this network yet. |
| Start Year | 2017 |
| Description | Cross Node informatics workshops |
| Organisation | Edinburgh-St Andrews Consortium for Molecular Pathology Node |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The Glasgow Molecular Pathology Node has led a series of calls and workshops across the Node network to provide the opportunity for each of the Nodes to learn about the bioinformatics work being undertaken and to facilitate discussion and to prioritise areas for further collaboration/cross Node training opportunities. In addition to an increased awareness of the specific work being undertaken a number of common themes were identified: data integration of multiomics; clinical data collection and integration; image analysis and training. The focus of ongoing workshops and discussions is to consider how the Node network can work together to address common challenges and support Node activities. |
| Collaborator Contribution | The informaticians associated with each Node have participated in calls, online seminars and workshops to share information, experiences and to offer solutions. Additionally the team in Manchester are organsing a cross Node informatics research symposium which provides informaticians with the opportunity to showcase the informatics work being undertaken across the Nodes. |
| Impact | No outcomes or impact have resulted from this network yet. |
| Start Year | 2017 |
| Description | Cross Node informatics workshops |
| Organisation | Newcastle Molecular Pathology Node |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The Glasgow Molecular Pathology Node has led a series of calls and workshops across the Node network to provide the opportunity for each of the Nodes to learn about the bioinformatics work being undertaken and to facilitate discussion and to prioritise areas for further collaboration/cross Node training opportunities. In addition to an increased awareness of the specific work being undertaken a number of common themes were identified: data integration of multiomics; clinical data collection and integration; image analysis and training. The focus of ongoing workshops and discussions is to consider how the Node network can work together to address common challenges and support Node activities. |
| Collaborator Contribution | The informaticians associated with each Node have participated in calls, online seminars and workshops to share information, experiences and to offer solutions. Additionally the team in Manchester are organsing a cross Node informatics research symposium which provides informaticians with the opportunity to showcase the informatics work being undertaken across the Nodes. |
| Impact | No outcomes or impact have resulted from this network yet. |
| Start Year | 2017 |
| Description | Cross Node informatics workshops |
| Organisation | Nottingham Molecular Pathology Node |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | The Glasgow Molecular Pathology Node has led a series of calls and workshops across the Node network to provide the opportunity for each of the Nodes to learn about the bioinformatics work being undertaken and to facilitate discussion and to prioritise areas for further collaboration/cross Node training opportunities. In addition to an increased awareness of the specific work being undertaken a number of common themes were identified: data integration of multiomics; clinical data collection and integration; image analysis and training. The focus of ongoing workshops and discussions is to consider how the Node network can work together to address common challenges and support Node activities. |
| Collaborator Contribution | The informaticians associated with each Node have participated in calls, online seminars and workshops to share information, experiences and to offer solutions. Additionally the team in Manchester are organsing a cross Node informatics research symposium which provides informaticians with the opportunity to showcase the informatics work being undertaken across the Nodes. |
| Impact | No outcomes or impact have resulted from this network yet. |
| Start Year | 2017 |
| Description | Cross Node informatics workshops |
| Organisation | University of Manchester |
| Department | Manchester Molecular Pathology Innovation Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The Glasgow Molecular Pathology Node has led a series of calls and workshops across the Node network to provide the opportunity for each of the Nodes to learn about the bioinformatics work being undertaken and to facilitate discussion and to prioritise areas for further collaboration/cross Node training opportunities. In addition to an increased awareness of the specific work being undertaken a number of common themes were identified: data integration of multiomics; clinical data collection and integration; image analysis and training. The focus of ongoing workshops and discussions is to consider how the Node network can work together to address common challenges and support Node activities. |
| Collaborator Contribution | The informaticians associated with each Node have participated in calls, online seminars and workshops to share information, experiences and to offer solutions. Additionally the team in Manchester are organsing a cross Node informatics research symposium which provides informaticians with the opportunity to showcase the informatics work being undertaken across the Nodes. |
| Impact | No outcomes or impact have resulted from this network yet. |
| Start Year | 2017 |
| Description | Institute of Infection, Immunity and Inflammation |
| Organisation | University of Glasgow |
| Department | Institute of Infection, Immunity and Inflammation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Post-doctoral research assistant now based in Professor Gerry Graham's lab, investigating IL-6 biology and its role in macrophage polarisation in ovarian clear cell carcinoma; research funding; animal models of ovarian cancer |
| Collaborator Contribution | Expertise in cytokine and chemokine biology; access to transgenic mouse models |
| Impact | No publications yet, but manuscript to be submitted later in 2019 |
| Start Year | 2017 |
| Description | Node training network and CM-Path |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | CM-Path initiative |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | The Glasgow Molecular Pathology Node training workstrand team have facilitated introductions to the lead of the training workstream for CM-Path. |
| Collaborator Contribution | Professor Louise Jones has participated in a number of Node network calls focussed on training and has provided updates on the activities being undertaken by CM-Path in regards to training. |
| Impact | n/a |
| Start Year | 2016 |
| Description | SMS-IC |
| Organisation | Stratified Medicine Scotland Innovation Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Joint working between the Glasgow Molecular Pathology Node and SMS-IC is providing infrastructure and workflows to deliver pan Scottish projects which include biospecimens and clinical data. The Node is contributing to the infrastructure required to access patient samples, to provide clinical annotation and to undertake next generation sequencing, including analysis and interpretation. Additionally the Node is facilitating access to pathology consultants for sample review and scoring. |
| Collaborator Contribution | SMS-IC co-ordinates delivery of the projects together with being the core provider for patient data aggregation and informatics services via the SMS Innovation Platform. SMS-IC provide informatics and IT developer expertise to build DataCommons which integrate patient data, clinical information and genomic data. SMS-IC have also been providing guidance and expertise to facilitate the accreditation of the Precision Medicine Laboratory at the University of Glasgow and provide project management support. |
| Impact | Successful InnovateUK grant application worth £1.7 million. |
| Start Year | 2015 |
| Title | Glasgow Cancer Assay |
| Description | The Glasgow Cancer Core panel was developed by GPOL for comprehensive profiling of actionable genomic events in solid tumors. This panel targets 174 genes for events including single nucleotide variants (SNVs), short insertion and deletions (indels), copy number variants (CNVs), large structure variants, and gene fusions. The Glasgow Cancer Assays require no special preparation and with even as little as 10ng of DNA, FFPE and fresh-frozen samples routinely yield clinical grade data. It is designed to be cost-effective and affordable for public healthcare providers. |
| IP Reference | |
| Protection | Copyrighted (e.g. software) |
| Year Protection Granted | 2019 |
| Licensed | Yes |
| Impact | This assay is available to order from Agilent Technologies as part of their Community Design Program. With the high-quality data produced by the SureSelect platform, delivered by a fast and automatable workflow, GPOL is leading the implementation of broad genomic testing. The assay based on the Glasgow Cancer Core panel is being used to screen for somatic cancer biomarkers, as well as current and emerging response and resistant markers for subject selection in clinical trials. The assay is being trialled by oncology researchers and healthcare groups in the UK and Italy. |
| Title | A novel technique to simultaneously detect drugs, drug metabolites, and endogenous urinary metabolites of patients taking antihypertensive drugs (drugomics) |
| Description | Drug non-adherence, particularly anti-hypertensives, is a significant health issue. An objective test for drug adherence to identify and manage non-adherent individuals is urgently needed. Current methods (questionnaires, pill-counts, and targeted LC-MS/MS) have considerable limitations. A robust drug screening method that addresses all these limitations is a priority. We have demonstrated the proof-of-concept of a novel screening method that allows accurate detection of drugs and their metabolites in patient spot urine samples. |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2017 |
| Development Status | Actively seeking support |
| Impact | n/a product currently under development |
| Title | Assay for homologous recombination deficiency in pancreatic cancer |
| Description | Development of a biomarker and assay to identify pancreatic ductal ademocarcinoma (PDAC) patients who are most likely to respond well to platinum therapies and be suitable for clinical trials including a PARP inhibitor. The current project will validate the biomarker and assay in a large cohort of patient samples. This is being funded by CiC funding. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2019 |
| Development Status | Actively seeking support |
| Impact | n/a |
| Title | Epigenetic biomarker signature for RA |
| Description | The team have discovered a molecular prognostic biomarker approach that can predict responsiveness to treatment. The approach uses chromosomal conformation loop analysis to identify responsiveness to cDMARDs in early RA patients. The molecular signatures we have discovered are present in whole blood and therefore the translatability of these biomarkers into the clinic is a viable approach. We foresee a QPCR-based clinical test(s) that can be performed on whole blood samples by NHS clinical laboratory staff prior to initiation of therapy. Importantly, there is currently no other way to determine whether or not a patient will respond to therapy. This would represent the first prognostic biomarker of its kind. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2018 |
| Development Status | Actively seeking support |
| Impact | n/a product under development |
| Title | Glasgow Cancer Assay |
| Description | The Glasgow Cancer Core panel was developed by GPOL for comprehensive profiling of actionable genomic events in solid tumours. It is designed to be cost effective for public healthcare providers. The assay is currently in validation stage in a healthcare network in Italy, and has been trialled by several UK NHS Boards and Trusts. It is being used to screen for somatic cancer biomarkers as well as current and emerging response and resistant markers in ongoing clinical trials. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Impact | The assay is available to order from Agilent Technologies as an off the shelf product. The assay is providing improved access to screening for biomarkers in clinical trials in the UK, and turnaround speed for real-world utilisation in a clinical context is currently under investigation. |
| URL | https://www.gpol.org/divisions/medical-genomics/sequencing/ |
| Title | Panel based diagnostic assay (cancer) |
| Description | A targeted enrichment NGS panel which allows in-depth molecular profiling and biomarker discovery/development for patients with pancreatic cancer |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Impact | n/a as the product is currently under development |
| Title | Point of care device for assessing risk |
| Description | The technology being developed is a point of care device that will allow simultaneous assessment of numerous metabolites on a single chip device. |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Impact | n/a product currently under development |
| Title | RNAseq panel (NIMA) |
| Description | This transcriptomic profile will be used to to guide treatment stratification in a subsequent proof-of-concept study and also possible experimental medicine or therapeutic proof-of-concept studies. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2017 |
| Development Status | Actively seeking support |
| Impact | n/a this product is currently under development |
| Title | Targeted RNAseq panel (RA) |
| Description | A patent application is currently being prepared for this product and therefore it is not possible to disclose any information. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2017 |
| Development Status | Actively seeking support |
| Impact | n/a as the product is still in development |
| Title | Polyomics integrated Metabolomics Pipeline |
| Description | Software tool for metabolomics analysis New software infrastructure, open access, to enable analysis of LC-MS datasets |
| Type Of Technology | Software |
| Year Produced | 2017 |
| Impact | Many people now have access to a platform to enable analysis of their LC-MS data |
| URL | http://polyomics.mvls.gla.ac.uk/ |
| Company Name | GABRIEL PRECISION ONCOLOGY LIMITED |
| Description | About Gabriel Gabriel Precision Oncology Limited was established in 2020 to make precision oncology a reality for all cancer patients. Gabriel is founded on a deep understanding of the entire clinical cancer pathway, including diagnostics, stratification, standard of care therapy and experimental treatment approaches. Through their combined experience, gleaned from leaderships roles in healthcare delivery, academic research and commercial drug development, the Gabriel team are focussed on democratising access to genomic analysis for cancer patients to maximise the benefits of current therapies and expedite the development of novel therapeutic approaches. |
| Year Established | 2020 |
| Impact | UNIVERSITY OF GLASGOW SPINOUT ENTERS ONCOLOGY COLLABORATION WITH CONGENICA Issued: Wed, 03 Feb 2021 07:00:49 GMT Gabriel Precision Oncology Limited (known as Gabriel) - a University of Glasgow spinout company - announces an important oncology collaboration with Congenica. Congenica is a digital health company enabling rapid and accurate analysis of complex genomic data to transform people's lives. Working together, the two teams will develop a new highly automated somatic cancer clinical interpretation software platform, which will support the use of multiple genomic assays in routine clinical practice. Andrew Biankin Professor Biankin's team at the University of Glasgow have developed software - a pipeline that detects mutations in the genome specifically for the analysis of sequencing data from cancer samples. The pipeline is able to detect all the different types of genomic variants that are relevant for cancer with a high degree of sensitivity and specificity, and has been optimised to produce high quality data from sequencing of formalin exposed DNA. Importantly, the collaboration will allow customers to use a single platform to analyse all types of mutations from different cancer gene panels, thereby overcoming a substantial challenge in oncology diagnostics and representing a major step forward for pathologists, haematologists and oncologists globally. Gabriel was founded by Professor Andrew Biankin, Dr Susanna Cooke and Dr Philip Beer. Between them, the founders have deep expertise and experience in cancer genomics and therapeutic development, encompassing the commercial, healthcare and academic sectors, and have played influential roles in national and international genomics consortia. Congenica has developed know-how and IP in the field of bioinformatics, genomics, software development and data architecture which it uses to develop commercial clinical decision support platforms using genomic data. Utilising this know-how, Congenica will work with Gabriel to build a platform that will support the interpretation of somatic cancer genomic data for both research and clinical diagnostic use. By incorporating the platform into clinical testing, the aim is that next generation sequencing can be more widely integrated into routine molecular pathology testing, driving efficiency in the diagnostic process. Freddie Sharkey, PhD, VP Oncology & EMEA Sales, said: "This collaboration signifies the expansion of Congenica's product platform into somatic cancer, a disease area which we believe can significantly benefit from our platform. Gabriel brings together extensive international genomics expertise and its platform has been developed specifically to work with tumour derived DNA. We look forward to working with Gabriel to further incorporate clinical genomics into routine cancer care." Andrew Biankin, University of Glasgow and Gabriel, said: "Still too few people have access to advanced molecular cancer diagnostics and as a consequence miss out on potential treatments and clinical trials. A distributed model where laboratories and health systems around the world can do their own tests for their own patients using a standardised and comparable analytical platform will enable more patients to access precision medicine. Congenica's technology is market-leading in terms of the rapid interpretation of genomic data and working together we believe that our platform will enable many more cancer patients to access new treatments." About Congenica Congenica is a digital health company enabling the rapid analysis and interpretation of genomic data, empowering researchers to provide life-changing answers that will in future improve wellbeing and disease management. Congenica's world-leading software enables rapid genomic data analysis at scale, performing 20x faster than industry averages and providing a 30% higher analytical yield, reducing genomic interpretation costs by up to 95%. Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service. About Gabriel Gabriel Precision Oncology Limited was established in 2020 to make precision oncology a reality for all cancer patients. Gabriel is founded on a deep understanding of the entire clinical cancer pathway, including diagnostics, stratification, standard of care therapy and experimental treatment approaches. Through their combined experience, gleaned from leaderships roles in healthcare delivery, academic research and commercial drug development, the Gabriel team are focussed on democratising access to genomic analysis for cancer patients to maximise the benefits of current therapies and expedite the development of novel therapeutic approaches. https://www.gla.ac.uk/news/headline_771751_en.html |
| Description | Andrew Biankin and Susie Cooke were speakers at Genomic Medicine 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr Susie Cooke presented "Bioinformatics for Clinical Cancer Genomics" and Andrew Biankin presented "Precision Oncology - from clinical trials to artificial intelligence" at Genomic Medicine 2019 in May 2019 |
| Year(s) Of Engagement Activity | 2019 |
| Description | Annual Node symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | The annual Node symposium is open to academics, clinicians and industry and features a series of presentations and posters aimed at highlighting the research being undertaken across the Glasow Molecular Pathology node. The symposium provides opportunities for questions, discussion and networking and the number of attendees and exhibitors increased from the previous year. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Annual Symposium of the Glasgow Molecular Pathology Node |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker to a mixed audience of NHS and Industry partners involving discover researchers in biomedicine, bioengineering, biostatistics and health economics. |
| Year(s) Of Engagement Activity | 2016,2017 |
| Description | British Heart Foundation research exhibition Scottish parliament |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Researchers from the cardiovascular workstrand and cardiovascular pathologists contributed to a British Heart Foundation research exhibition at the Scottish parliament. A number of slides with cardiovascular tissue samples were shown under a microscope and also broadcast on to a screen for people to see actual real life images of the various materials. |
| Year(s) Of Engagement Activity | 2017 |
| Description | British Science Week - Glasgow Science Centre |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Representatives from Glasgow Molecular Pathology Node, including pathologists, participated in British Science Week at the Glasgow Science Centre on Thursday 16th March. Approximately 120 primary school children took part in activities which demonstrated DNA structure and function, mutations, the role of pathologists in diagnosis and treatment of patients and precision medicine. |
| Year(s) Of Engagement Activity | 2017 |
| Description | CEO Inovate UK visit - Dr Ruth Mckernan |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Visit and tour of ICE by Ruth McKernand with strategic discussions on future engagement of ICE and Stratified Medicine Scotland in Precision Medicine |
| Year(s) Of Engagement Activity | 2017 |
| Description | CellSearch and Deparray user group meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The Node project manager attended this event to gain a deeper understanding of how the DepArray technology is being used and the potential of this technology for clinical use. Colleagues from Menarini are actively engaged in Node industry engagement and networking events and opportunities for collaboration using this technology are now being explored across the Node research workstrands. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Confederation of Cancer Biobanks conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Approximately 120 people from across the UK attended a conference titled 'Working together: Collaboration in the cancer biobanking landscape'. The meeting was aimed at maximising opportunities in biobanking and included a presentation from the Node cancer workstrand lead (Professor Andrew Biankin) on the Scottish Genomes Partnership discussing challenges and opportunities for biobanking. |
| Year(s) Of Engagement Activity | 2016 |
| Description | East Midlands Breathomics Molecular Pathology Node Annual General Assembly |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | not sure what to write here |
| Year(s) Of Engagement Activity | 2016 |
| Description | Explorathon - European Researchers Week |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | The Molecular Pathology Node organised a number of activities to introduce pathology, molecular pathology, stratified medicine and genetics to the public. This event raised awareness of the Node and gave the public the opportunity to learn about what pathologists do to understand causes, mechanisms and effects of diseases. This event highlighted the fact that pathology applies to the living and that pathologists make a huge contribution to the care of living patients. Additionally this event introduced the public to personalised or stratified medicine and allowed them to understand that not everyone who is classified with the same disease will necessarily experience the same rate of disease progression or respond equally well to drugs. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Forensic Mortuary Rapid Improvement event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Professional development event held in ICE developing collaborative links with Forensic Pathologists |
| Year(s) Of Engagement Activity | 2017 |
| Description | Glasgow Molecular Pathology Node Annual Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Approx 120 people attended the annual Glasgow Molecular Pathology Node symposium to hear about the research being supported by the Node to drive the development and adoption of new diagnostics test for clinical practice. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Glasgow Molecular Pathology Node Annual Symposium 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The annual Glasgow Molecular Pathology Node symposium described the research and engagement being supported by the Node to drive the development and adoption of new diagnostics test for clinical practice. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.gla.ac.uk/colleges/mvls/node/newsandevents/headline_647440_en.html |
| Description | Glasgow Molecular Pathology Node Launch event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | The Glasgow Molecular Pathology Node launch event presented the Node infrastructure, research and outputs to academics, NHSGG&C, industry and the Node network. Opportunities for engagement with the Node were also highlighted. Approximately 100 people attended the event and a number of potential parternship opportunities were identified with industry. These opportunities are currently being progressed. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Group members Dr Susie Cooke and Mrs Donna Ramsay attended the MHRA Laboratories (GLP, GCP & GMPQC) Symposium in February 2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This meeting provided essential contacts and up to date information on MHRA laboratory regulatory requirements. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://mhralabs.co.uk/home |
| Description | Harper Van Steenhouse Biclavis |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Detailed discussions of tenancy within wider clinical innovation zone |
| Year(s) Of Engagement Activity | 2017 |
| Description | Improving the focus of precision medicine: The role of health technology assessment |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Approximately 100 people attended a workshop that considered issues related to the successful development of precision medicine technologies; the potential role of health technology assessment analysis and thinking in the selection of candidate technologies and the design of studies that will provide compelling evidence. The audience were introduced to the Glasgow Molecular Pathology Node and the role of health technology assessment across the Node disease-based workstreams to prioritise promising biomarkers and provide a framework for commercial development. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Intel visit - |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | First meeting with senior technical staff Intel C Rhodes and C Emerson to showcase facilities (Genomics Pathology and Imaging) and to discuss future strategic collaborations |
| Year(s) Of Engagement Activity | 2017 |
| Description | International Cancer Genome Consortium (ICGC) PanCancer Analysis of Whole Genomes (PCAWG) Working Group Meeting, Seoul |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Professor Biankin participated in the working group meeting which has an international participation. |
| Year(s) Of Engagement Activity | 2017 |
| Description | International Molecular Pathology Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Karin Oien presented on the Molecular Pathology Nodes to demonstrate how clinicians, academics and industry are working together to build capacity in molecular pathology to maximise the potential patient and economic benefits of stratified medicine. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Invited Speaker - Scottish Oncology Summit |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Scottish Oncology community shared best practices and participated in debate from renowned experts on Oncology. |
| Year(s) Of Engagement Activity | 2016,2017 |
| URL | http://www.synaptik.info/events/scottish-oncology-summit-september-2017/ |
| Description | Invited Speaker at British Association for Cancer Research Development of Medicines Annual Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker to an audience of biologists, chemists and practicing oncologists. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Invited Speaker at European Alliance for Personalised Medicine, Belfast 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Showcased the Precision Panc project. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Invited plenary talk on the use of technology in genomics education and research, given in October 2016, in Taiwan |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited plenary talk given on Sunday 30th October at a conference on Genetics, Reproductive Genetics and Genomics in Changhua, Taiwan in the David Landsborough International Conference Hall. This talk was the first of 9 plenary talks at the symposium and it concerned the use of technology to enrich genomics education and research. It was delivered within the session entitled Genetics, Medicine and Biology. Several professionals spoke to me afterwards to request further information, including a professor & senior consultant of the Karolinska Institute, Stockholm (and ex-president of the Swedish Society of Medical Genetics). |
| Year(s) Of Engagement Activity | 2016 |
| Description | Laboratory Medicine Grand Rounds |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Naomi presented at the NODE laboratory Medicine Grand Rounds in January 2018. Her presentation was on the potential of NMR and MS metabolomics to identify biomarkers for disease. She used examples from her own work and collaborations: the identification of phenylalanine as a potential biomarker for incident heart failure hospitalisation, associations of amino acids with complications of type 2 diabetes, carboxymethyl lysine as a potential biomarker for cardiovascular disease and un-targeted metabolomics use in investigation of CADASIL. This work allowed Naomi to reach out to a wider audience and to introduce pathologists, particularly trainees, to the potential of metabolomics in laboratory medicine. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.gla.ac.uk/schools/medicine/research/medicalgeneticsandpathology/eventsandseminars/ |
| Description | MMPathIC industry forum |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Representatives from the Glasgow Molecular Pathology Node participated in this forum which was aimed at helping to help define a roadmap to market for novel diagnostics and tests through a two-way dialogue between academics and industry. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Medgenome visit : Lakshmi Santhosh & Michael Nemzek |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Visit and scientific discussions with senior representative MedGenome |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.medgenome.com/ |
| Description | Media Interview during UK Oncology Forum 2018 (Pancreas Cancer) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Discussion with professional media on pancreatic cancer during UK Oncology Forum, Liverpool, 2018 |
| Year(s) Of Engagement Activity | 2018 |
| Description | Media Presentation on lenvatinib in HCC during American Society of Clinical Oncology, 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Discussion on management of HCC among medical media |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.gla.ac.uk |
| Description | Metabolomics Masterclass at the University of Cape Town (S. Africa) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Metabolomics workshop in South Africa. I was invited to teach the section on NMR metabolomics and to demo the PicoSpin, a 45 MHz bench-top NMR spectrometer. I also included a hands-on data analysis activity using Chenomx NMR profiling software. The reception was very enthusiastic and we have been invited back next year. Attendees were working on a variety of metabolomics projects, including HIV and tuberculosis. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Metabolomics Workshop University of Pretoria (South Africa) 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Metabolomics workshop in South Africa. I was invited to teach the section on NMR metabolomics and to demo the PicoSpin, a 45 MHz bench-top NMR spectrometer. I also included a hands-on data analysis activity using Chenomx NMR profiling software. The reception was very enthusiastic and we have been invited back next year. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Molecular Pathology Node Forum |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This event is listed under Molecular Pathology Node return but there was significant crossover in relation to future planning with ICE. |
| Year(s) Of Engagement Activity | 2017 |
| Description | NHS Research Scotland (NRS) Annual Conference |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Glasgow Molecular Pathology Node set up an exhibition stand at the NHS Research Scotland (NRS) Annual Conference, Scotland's leading clinical research conference, that brings together almost 500 delegates across NHS, academia, industry and third sector. Representatives from the Node engaged in discussions with clinicians, researchers, academics and representatives from industry to raise awareness of the Node and its objectives. |
| Year(s) Of Engagement Activity | 2016 |
| Description | NHS Research Scotland (NRS) Annual Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Node workstrand leads for Cancer (Professor Andrew Biankin) and Inflammation (Professor Iain McInnes) presented as part of the Precision Medicine session. These presentations updated on the Scottish Ecosystem for Precision Medicine and demonstrates Scotland's strengths in coordinating clinical, laboratory and informatics resources to deliver the right drug for the right patient at the right time. |
| Year(s) Of Engagement Activity | 2016 |
| Description | NHSGGC Medical Genetics |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | This presentation higlighted the Molecular Pathology Node and the training opportunities available through the Node, in particular the Masters in Molecular Pathology. Following this presentation 5 scientists from this department applied for and were accepted into the course. |
| Year(s) Of Engagement Activity | 2016 |
| Description | National Pathology Week - public engagement event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Pathologists, geneticists, clinical and biomedical scientists from the Glasgow Molecular Pathology Node set up an booth with a number of interactive activities in the main atrium of the Queen Elizabeth University Hospital. The Node representatives described the roles of pathologists and scientists, the pathway of tissue from biopsy to diagnosis, different pathological tests and the work of the Glasgow Molecular Pathology Node. Our visitors learnt about the importance of genes in cancer and its treatment and, with an interactive bead game, had a go at 'making' complementary DNA by hand and found that it's hard to do accurately and quickly! Feedback showed that patients were interested in the differences in genes and relating these to their own illnesses, and hospital staff were fascinated by molecular pathology and its progress. |
| Year(s) Of Engagement Activity | 2016 |
| Description | News Article: Dr David Chang |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Dr David Chang was interviewed by the Daily Record about the groundbreaking importance of Glasgow-based pancreatic cancer trial. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.dailyrecord.co.uk/lifestyle/health-fitness/pancreatic-cancer-research-glasgow-university... |
| Description | Participant at Inspire2Live Annual Congress, Amsterdam |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Collaboration with key members of the European cancer community. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Pathology Rapid Improvement Event Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Professional development of Pathologists |
| Year(s) Of Engagement Activity | 2017 |
| Description | Phillips digital pathology user group meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | This user group meeting was aimed at current and potential users of Phillips digital pathology platforms and provided the opportunity to hear about how clinical sites are using digital pathology to support clinical delivery. Participation in this event has led to the exploration of clinical trial for some digital pathology software within NHSGGC and supported by the Node. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Presentation to Glasgow Biomedicine |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | The project manager presented the progress of the Glasgow molecular pathology Node to date to the Glasgow Biomedicine board (which features representatives from the three universities in Glasgow and NHS Greater Glasgow & CLyde) to support sustainability planning. The board discussed the opportunities for closer integration and support for the Node and requested to be kept informed of Node progress and future plans. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Promoting partnerships - PRecision diagnOstics: MOlecular and imagING' |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Regular scientific review and Outreach meeting for MRC pathology node |
| Year(s) Of Engagement Activity | 2017 |
| Description | Promoting partnerships network meetings |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The 'Promoting partnerships: precision diagnostics molecular and imaging' network brings together researchers, clinicians, biomedical & clinical scientists, health economists, translational and commercialisation colleagues and industry representatives supporting the development of precision diagnostics (molecular and imaging) and associated technologies or software. These network meetings highlight research being undertaken across the College of Medical, Veterinary and Life Sciences; relevant industry technologies & developments to support development of precision diagnostics and enable networking and knowledge exchange across a diverse range of professionals. Additionally they will update on initiatives which support the development of diagnostics such as the Glasgow Molecular Pathology Node and the Imaging Centre of Excellence. The meetings are aimed at: supporting the identification of potential collaborative research; discussing common challenges; highlighting forthcoming events and funding opportunities and provide a regular forum for industry-academic networking. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Promoting partnerships workshop September 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Participants in this event included academics, clinicians and industry and the aim of the event was to ensure that stakeholders' group are aware of what the node can offer; to support the community develop actions in order to work together effectively and to provide a forum for focussed networking. This event led to 3 industry partnerships being pursued by the Node. |
| Year(s) Of Engagement Activity | 2017 |
| Description | QEUH - Laboratory Medicine Poster day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Laboratory Medicine building at the Queen Elizabeth University Hospital hosts an annual poster day which enables students, researchers and clinicians to present research across a range of disciplines. There were 29 posters across a variety of disciplines such as pathology, molecular diagnostics and biochemistry and the award for best poster was presented by the Glasgow Molecular Pathology Node. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Quotient SDI visit 11/07/17 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Visit of Quotient Biosciences management - in collaboration with SDI to see facilities and as potential long term tenants |
| Year(s) Of Engagement Activity | 2017 |
| Description | Roche Diagnostics Visit |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Visit and tour of facilities to senior representatives - mainly genomics and pathology oriented but cross references to ICE |
| Year(s) Of Engagement Activity | 2017 |
| Description | Roche R&D insights |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The project manager for the Glasgow Molecular Pathology Node attended this event and engaged in discussions with clinicians, researchers, academics and representatives from industry to raise awareness of the Node and its objectives. This has resulted in the development of a relationship with Roche Diagnostics which has included visits to the Queen Elizabeth University Hospital and teleconferences to identify potential areas of collaboration/support. Roche Diagnostics are supporting a programme of activities organised by the Node aimed at increasing academic-industry engagement to facilitate translation and commercialisation of research. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Science Week - St Francis primary |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | The Molecular Pathology Node participated in a Science Fair at St Francis primary school and delivered a number of activities to introduce pathology, molecular pathology, stratified medicine and genetics to the children and their parents. This event gave the children the opportunity to learn about what pathologists do to understand causes, mechanisms and effects of diseases. This event highlighted the fact that pathology applies to the living and that pathologists make a huge contribution to the care of living patients. Additionally this event introduced the public to personalised or stratified medicine and allowed them to understand that not everyone who is classified with the same disease will necessarily experience the same rate of disease progression or respond equally well to drugs. A number of children reported that they wanted to be geneticists or pathologists following the event. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Scottish Metabolomics Network Symposium 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Naomi was lead organiser for the Scottish Metabolomics Network Symposium 2017 which was held at the City of Glasgow College: Riverside Campus in November. The network is an affiliation of the Metabolomics Society and aims to bring together researchers in the field of metabolomics and lipidomics to share knowledge. The event was sold out (130 attendees in total) with a 50% increase in the number of attendees and three potential sponsors had to be turned away due to lack of space. We were approached by Glasgow City Council and invited to a civic reception. The event is open to undergraduates, post-graduates, early career researchers (post-doctoral researchers, fellows, research technicians and principle investigators form any country - although most were based in Scotland some did travel from England to attend. There was an increase in attendees from industry too. The feedback was very positive with 54% rating it as excellent and 44% rating it as good. 100% said they would attend the symposium in future. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://scottishmetabolomics.net/events/ |
| Description | Scottish Metabolomics Network Website and Newsletter |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Naomi is content manager for the Scottish Metabolomics Network website and editor of the quarterly newsletter published on this website. The website and newsletter are aimed primarily at researchers in metabolomics. However, it is accessible to the public and to industry. There were over 1500 unique visitors to the website in the last year. Naomi updates the membership pages, the event pages and the newsletter. As part of editing the newsletter, Naomi liaises with researchers in the Scottish Metabolomics Network and now includes a "lab of the quarter" piece to allow specific laboratories to highlight what they can do and encourage collaboration. |
| Year(s) Of Engagement Activity | 2017,2018 |
| URL | http://scottishmetabolomics.net/newsletter/ |
| Description | Scottish Parliament Event with Pancreatic Cancer Scotland and Pancreatic Cancer UK |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | To mark Pancreatic Cancer Awareness Month, Clare Adamson MSP in conjunction with PCS and PCUK hosted an event to which Dr David Chang, Dr Susie Cooke and Sancha Martin represented the group. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Speaker at Research Ethics Service Annual Training Day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Highlighting the importance of translational research to the expert and lay members of the West of Scotland Research Ethics Service. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk (Oct. 2016) re the Training Workstrand of the Glasgow Molecular Pathology Node at the Node's inaugural symposium at the Glasgow Hilton Grosvenor Hotel. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The inaugural annual symposium of the University of Glasgow MRC Molecular Pathology Node took place on Monday 24 October at the Glasgow Hilton Grosvenor Hotel. It featured talks from Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, Professor Dame Anna Dominiczak, as well as from the Director of the MRC Molecular Pathology Node, Dr Karin Oien. The symposium also featured contributions from Dr Desmond Walsh, Head of Populations and Systems Medicine Board and Lead of Stratified Medicine at the MRC and also David Sibbald, the Executive Chairman of Aridhia. There were approximately 150 delegates registered for the event, comprising academia, NHS and industry partners. Delegates also included representatives from official partners of the Node. Importantly, the symposium highlighted the importance of a collaborative approach to precision medicine and it generated significant further interest from additional partners. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Talk (Sept. 2018) re the Training Workstrand of the Glasgow Molecular Pathology Node at the Node's 2018 symposium at the Queen Elizabeth University Hospital, Glasgow, UK |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Gave an invited talk (on 12th Sept. 2018) re the Training Workstrand of the MRC Glasgow Molecular Pathology Node at the Node's 2018 symposium at the Queen Elizabeth University Hospital, Glasgow, UK. Involved the audience. Many related questions received and much interest expressed following the talk. This annual symposium of the University of Glasgow MRC Molecular Pathology Node took place at the QEUH Teaching and Learning Centre. It featured talks from Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, Professor Dame Anna Dominiczak, as well as from the Director of the MRC Molecular Pathology Node, Dr Karin Oien. The symposium also featured many other important contributions. There were approximately 150 delegates registered for the event, comprising academia, NHS and industry partners. Delegates also included representatives from official partners of the Node. Importantly, the symposium highlighted the continued importance of a collaborative approach to precision medicine. |
| Year(s) Of Engagement Activity | 2018 |
| Description | The importance of acids and bases for Explorathon 17 School Activity |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Naomi visited St Rose of Lima Primary School as part of the Explorathon Schools program. She taught 30 students in primary 7 about the importance of acids and bases. She led experiments using red cabbage juice as a chromogen that changes colour depending on the pH - so the pupils could see the effect of adding lemon juice or vinegar compared to adding detergent or bicarbonate powder. She then led a paper chromatography experiment - looking at the migration of different felt pen inks in filter paper. Naomi talked about the importance of pH in chromatography and how this can be exploited in other forms of chromatography. She also discussed the importance of pH in health and how this is regulated. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.explorathon.co.uk/glasgow |
| Description | Trainer at the EMBO EBI Practical Course on Metabolomics Informatics for Life Scientists in Cambridge |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | PhD students and postdoctoral researchers from across Europe apply to attend and 30 out of 150 applicants are selected. I was invited to teach the NMR spectroscopy part of this course. I met other researchers from prestigious metabolomics laboratories and have discussed potential projects with them for collaboration in the future. In addition to giving students an introductory lecture on proton NMR spectroscopy in metabolomics, I lead an in silica exercise where students used Chenomx to analyse some example spectra downloaded from MetaboLights. Naomi wrote a piece in the February 2018 edition of the Scottish Metabolomics Newsletter about her rewarding experiance teaching on this course: http://scottishmetabolomics.net/newsletter/. She also recieved some very positive feedback from a trainee: "Thank you for your NMR lecture. Even though I've had several NMR courses throughout studying chemistry I've never quite understood how it works. You were the first person that could break it down for me". |
| Year(s) Of Engagement Activity | 2017,2018 |
| URL | https://www.ebi.ac.uk/training/events/2018/embo-practical-course-metabolomics-bioinformatics-life-sc... |
| Description | University of Glasgow Industry day/ICE opening |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The Node exhibited at Univesity industry day which is aimed at increasing networking and collaboration between the university and industry. Participating in this event raised awareness of the Node and the support that it provides to academics and industry for the development of molecular diagnostics. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Visif of Angus Lamond University of Dundee |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Discussion on closer links between University Dundee cell based imaging Mas spec and ICE |
| Year(s) Of Engagement Activity | 2017 |